TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02849587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will smoke a cannabis cigarette ad libitum as per their usual routine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will smoke a cannabis cigarette ad libitum as per their usual routine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Description: Participants will smoke a cannabis cigarette ad libitum as per their usual routine
Study: NCT01710020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 10 mg oral powder for constitution
Study: NCT02658266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based resistance training
Description: The participants in the intervention group will receive an individualized resistance training program. The individual adjustments in load will will be made from the results of the muscle function and muscle strength tests. The resistance training will be home based and performed 3 times per week 10-12 reps 2 sets 12 weeks. Increment of load will be performed continuously according to rating of perceived exertion.
Study: NCT02208544

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diagnostic Thyroid Surgery
Description: Diagnostic Thyroid Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Thyroid Surgery
Description: Diagnostic Thyroid Surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound of the head and neck
Description: Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm

Intervention type: RADIATION
Group type: OTHER
Intervention: FDG-PET/CT
Description: Head and Neck FDG-PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Description: Head and Neck FDG-PET/CT
Study: NCT01205347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80mg
Description: Simvastatin 80mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 10mg
Description: Simvastatin 10mg once a day
Study: NCT00128661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
Description: Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A inactivated virus vaccine
Description: Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule
Study: NCT04202497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-418
Description: TAK-418 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-1054 (radiotracer)
Description: \[18F\]MNI-1054 injection.
Study: NCT01518569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ulinastatin
Description: ulinastatin 5000 unit/kg iv before the initiation of CPB

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (the same amount of normal saline) iv before the initiation of CPB
Study: NCT03119948

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin injection
Description: Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo injection and botulinum toxin injection
Description: Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus..~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment.
Study: NCT05545176

Intervention type: OTHER
Intervention: termination of resuscitation rules
Description: Use retrospective data to analyze the accuracy termination of resuscitation rules and further develope a termination of resuscitation rule.
Study: NCT03668639

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Weekly administration of dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 for five weeks.
Study: NCT02420197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary rehabilitation program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program
Study: NCT01908504

Intervention type: OTHER
Group type: OTHER
Intervention: PET-CT
Description: At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
Study: NCT01020877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Vaginal Gel, 0.75%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Vaginal Gel, 0.75%
Study: NCT01088984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study: NCT01201577

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium longum BB536
Description: 2 capsules od

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active hexose correlated compound (AHCC)
Description: One capsule tds

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)
Description: One capsule tds (prebiotic) and two capsules od (probiotic)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch placebo capsule
Description: One capsule tds and two capsules od

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: 250mg od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 250mg od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 250mg od
Study: NCT01201577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 250mg od
Study: NCT01982305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulator
Description: Axillary nerve anatomy lecture plus training with the simulator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cadaver
Description: Axillary nerve anatomy lecture plus training with the cadaver model.
Study: NCT04730141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient mobilization with pre-operative mobilization training and mobilization protocol
Description: Postoperative mobilization for the first 24 hours
Study: NCT03245905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 30mg orally BIW. Treatment cycles are repeated every 3 weeks.The maximum duration of treatment is 2 years.
Study: NCT03610711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg administered IV over 30 minutes every 2 weeks for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg administered IV over 30 minutes every 2 weeks for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: every 2 weeks for one year
Study: NCT01006980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg (as 240 mg tables) orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 1000 mg/m2 intravenously every 3 weeks
Study: NCT03795753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F2S Communicator
Description: The communicator will be attached to the BPAP/CPAP mask. The study coordinator will ENABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-functioning Communicator
Description: The communicator will be attached to the BPAP/CPAP mask. The study coordinator will DISABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period.
Study: NCT03438357

Intervention type: OTHER
Intervention: Analysis of cerebral MRI with automatic segmentation software
Description: Pixyl.Neuro software versus manual analysis of lesions
Study: NCT00835744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clomiphene citrate
Description: ovulation induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gonadotropins
Description: ovulation induction
Study: NCT01692951

Intervention type: OTHER
Intervention: serum sample
Description: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank

Intervention type: OTHER
Intervention: serum sample
Description: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank

Intervention type: OTHER
Intervention: serum sample
Description: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank

Intervention type: OTHER
Intervention: serum sample
Description: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank
Study: NCT00237731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: morphine 0.05

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: morphine 0.10
Study: NCT02869529

Intervention type: OTHER
Intervention: Data collection
Study: NCT01185275

Intervention type: DEVICE
Intervention: Alair system
Description: Bronchial thermoplasty
Study: NCT03867695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution
Study: NCT03425097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine 180 mg in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine 180 mg in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Cap
Description: Placebo cap in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Cap
Description: Placebo cap in the morning
Study: NCT00515671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery
Description: a structured curriculum to help mental health consumers manage their illnesses and pursue goals related to recovery from mental illness

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Problem Solving
Description: Weekly problem-solving support group
Study: NCT04631159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health2Sync app and report blood glucose data weekly
Description: Patients will need to download and use the Health2Sync app and report blood glucose data weekly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: self-manage
Description: Patients will be asked to self-manage and there is no intervention during the tracking process
Study: NCT03857698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Stabilization Exercise
Description: In the first session, breathing control and alet abdominal hallawing of movement will be taught to the patients with the help of the pressure biofeedback device. The degree of difficulty of the exercises will be improved by using different positions, by adding rotations to the motion, making the pelvic control more difficult and increasing the number of repetitions. In case of exacerbation of symptoms, the level will not be advanced. Exercises will be advanced according to the patient's initial level and response to exercise.~* Consecutive shoulder flexion and extension in supine~* Building a bridge~* Lower body and hip flip~* Single leg extension with bilateral arm elevation~* Resilient leg stretch with bilateral arm elevation~* Hip external rotation in lateral hospitalization~* Side-lying arm opening~* Shoulder girdle retraction on ball, horizantal abduction and extension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Stabilization Exercise
Description: In the first session, breathing control and alet abdominal hallawing of movement will be taught to the patients with the help of the pressure biofeedback device. The degree of difficulty of the exercises will be improved by using different positions, by adding rotations to the motion, making the pelvic control more difficult and increasing the number of repetitions. In case of exacerbation of symptoms, the level will not be advanced. Exercises will be advanced according to the patient's initial level and response to exercise.~* Consecutive shoulder flexion and extension in supine~* Building a bridge~* Lower body and hip flip~* Single leg extension with bilateral arm elevation~* Resilient leg stretch with bilateral arm elevation~* Hip external rotation in lateral hospitalization~* Side-lying arm opening~* Shoulder girdle retraction on ball, horizantal abduction and extension
Study: NCT04604574

Intervention type: OTHER
Group type: OTHER
Intervention: Indigenous Healing and Seeking Safety
Description: Indigenous Healing and Seeking Safety Intervention: Initial 90-minute meetings will be conducted with the participants; during these meetings, participants will receive information about IHSS, traditional healing, sharing circles, sweat lodge ceremonies, and program details. The sharing circles will take place at Benbowopka Residential treatment Centre in Blind River, Ontario. Each of the sharing circles will be cofacilitated by two Indigenous health-care workers. These facilitators will organize and lead sharing circles daily throughout the 28-day treatment cycle. Each sharing circle will be two hours long. The Seeking Safety program consists of up to 25 treatment topics that aim to teach participants a variety of skills. The majority of topics address the cognitive, behavioral, interpersonal, and case management needs of persons with SUD and posttraumatic stress disorders (PTSD) (Najavits, 2002a). The treatment will adhere to the concept of Two-Eyed Seeing and cultural sensitivity.
Study: NCT04542213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin tablet
Description: Linagliptin 5mg once daily plus a basal-bolus insulin scheme

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Basal-bolus insulin scheme
Study: NCT02622243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: long acting muscarinic antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrronium
Description: long acting muscarinic antagonist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: inhaler device used to deliver active tiotropium or placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: inhaler device used to deliver active tiotropium or placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breezehaler
Description: inhaler device used to deliver active glycopyrronium or placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breezehaler
Description: inhaler device used to deliver active glycopyrronium or placebo
Study: NCT02488226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaze-contingent eye-tracking technology
Description: When participants look away from a prototypical or expected norm, their gaze patterns are redirected to those prototypical locations.
Study: NCT01674829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE
Description: Transplantation of MA09-hRPE cells accoding to the assigned dose group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE
Description: Transplantation of MA09-hRPE cells accoding to the assigned dose group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE
Description: Transplantation of MA09-hRPE cells accoding to the assigned dose group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE
Description: Transplantation of MA09-hRPE cells accoding to the assigned dose group
Study: NCT02944201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will give twice daily until prostatectomy
Study: NCT05758948

Intervention type: DIAGNOSTIC_TEST
Intervention: NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue
Description: In patients with denovo metastatic breast cancer blood and tissue sample will be collected and then further analysed using NGS in order to detect somatic and germline pathogenic variants
Study: NCT05246891

Intervention type: OTHER
Intervention: rehabilitation nursing
Description: Functional respiratory rehabilitation and motor exercise plan.

Intervention type: OTHER
Intervention: rehabilitation nursing
Description: Functional respiratory rehabilitation and motor exercise plan.
Study: NCT01878903

Intervention type: OTHER
Intervention: Electronic VAS
Description: Post-opearive pain patients will be assessed using electional VAS and verbal NRS
Study: NCT05398406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAP Block group
Description: TAP Block: the US probe was placed on the imaginary line connecting the anterior superior iliac spine and the umbilicus. The ilioinguinal and iliohypogastric nerves in the fascia of the internal obliq and transverse abdominis muscles were visualized by US. A total of 40 ml of local anesthetic was infiltrated ESP Blok : a 100 mm 21G peripheral nerve block needle was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. 40 ml of the prepared solutions were injected PVB: In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral block group
Description: In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®, USA) was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made bilaterally in the form of 20+20 ml.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector spinae block group
Description: In the lateral decubitus position, a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA) was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. A total of 40 ml of the prepared solutions were injected bilaterally as 20+20 ml.
Study: NCT04448119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir is the experimental drug. The dosage for favipiravir to be used in this study for prophylaxis is 1600 mg (8 x 200 mg tablets) orally twice daily on day 1 followed by 800 mg (4 x 200 mg tablets) orally twice daily on days 2-25. The dose of favipiravir for treatment is 2000 mg orally twice daily on day 1, the 1000 mg orally twice daily for 13 additional days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Favipiravir Placebo
Description: Favipiravir Placebo is the placebo drug. For chemoprophylaxis, the dosage of favipiravir placebo is 8 tablets orally twice daily on day 1, followed by 4 tablets twice daily from days 2-25. The dosage of favipiravir placebo for treatment is 10 tablets orally twice daily on day 1, followed by tablets twice daily from days 2-14.
Study: NCT00097214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8.